Edition:
United States

DBV Technologies SA (DBVT.OQ)

DBVT.OQ on NASDAQ Stock Exchange Global Select Market

18.68USD
22 Oct 2018
Change (% chg)

$-0.23 (-1.22%)
Prev Close
$18.91
Open
$19.21
Day's High
$19.32
Day's Low
$18.66
Volume
39,673
Avg. Vol
41,723
52-wk High
$28.49
52-wk Low
$16.65

Latest Key Developments (Source: Significant Developments)

DBV Technologies Announces Result From Phase II Study of Viaskin Milk
Tuesday, 27 Feb 2018 02:57am EST 

Feb 27 (Reuters) - DBV TECHNOLOGIES SA ::ANNOUNCED ON MONDAY, RESULT FROM PHASE II STUDY OF VIASKIN MILK IN MILK-ALLERGIC PATIENTS.POSITIVE PRELIMINARY RESULTS SUPPORT VIASKIN MILK’S POTENTIAL AS THE FIRST TREATMENT FOR PATIENTS SUFFERING FROM IGE-MEDIATED COW’S MILK PROTEIN ALLERGY (CMPA).A STATISTICALLY SIGNIFICANT DESENSITIZATION TO MILK WAS OBSERVED IN CHILDREN AGES TWO TO 11 TREATED WITH VIASKIN MILK 300 ΜG FOR 12 MONTHS .COMPANY EVALUATING OPTIMAL DOSING/PATIENT POPULATION FOR FUTURE STUDIES.ANNOUNCES EVALUATING THE EFFICACY AND SAFETY OF THREE DOSE REGIMENS OF VIASKIN MILK (150 ΜG, 300 ΜG, 500 ΜG) IN 198 PATIENTS FOR THE TREATMENT OF IGE-MEDIATED.  Full Article

DBV Technologies Cash And Cash Equivalents At Dec. 31 Down At 137.9 Million Euros
Tuesday, 20 Feb 2018 01:30am EST 

Feb 20 (Reuters) - Dbv Technologies Sa ::‍CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2017, WERE EUR 137.9 MILLION, VERSUS EUR 256.5 MILLION YEAR AGO.  Full Article

Reg-Dbv Technologies Provides Update On Regulatory Progress For Viaskin Peanut
Wednesday, 14 Feb 2018 01:30am EST 

Feb 14 (Reuters) - Dbv Technologies Sa ::REG-DBV TECHNOLOGIES PROVIDES UPDATE ON REGULATORY PROGRESS FOR VIASKIN PEANUT.FDA AGREED TO SUBMISSION OF A BIOLOGICS LICENSE APPLICATION (BLA) FOR TREATMENT OF PEANUT ALLERGY IN CHILDREN AGED 4 TO 11.DBV REMAINS ON TRACK TO SUBMIT ITS BLA IN SECOND HALF OF 2018..  Full Article

DBV Technologies says Viaskin Peanut study demonstrates good tolerance and safety of product
Monday, 20 Nov 2017 02:20am EST 

Nov 20 (Reuters) - DBV TECHNOLOGIES SA ::SAYS STUDY DEMONSTRATES GOOD TOLERANCE AND SAFETY OF PRODUCT, COMPARABLE TO PREVIOUS STUDIES.FIST PERIOD OF STUDY COMPARED SAFETY OF TREATMENT WITH VIASKIN PEANUT 250 ΜG TO PLACEBO FOR 6 MTHS.RESULTS WILL SERVE AS A BASIS FOR PLANNED DISCUSSIONS WITH REGULATORY AUTHORITIES.SOME SERIOUS ADVERSE EVENTS WERE OBSERVED IN THE TRIAL.PATIENTS WHO COMPLETED FIRST PART OF STUDY WILL RECEIVE ACTIVE TREATMENT FOR 36 MTHS.  Full Article

DBV Technologies ‍announces positive data from Phase IIb trial and long-term study of Viaskin Peanut​
Tuesday, 14 Nov 2017 11:30am EST 

Nov 14 (Reuters) - DBV TECHNOLOGIES SA ::‍ANNOUNCES PUBLICATION OF POSITIVE DATA FROM PHASE IIB TRIAL AND LONG-TERM STUDY OF VIASKIN PEANUT​.‍PRIMARY ENDPOINT OF PHASE IIB STUDY WAS MET AFTER 12 MONTHS OF TREATMENT​.‍LONG-TERM EXTENSION DATA SHOWED TREATMENT BENEFIT INCREASES OVER TIME​.‍ONGOING VIASKIN PEANUT PHASE III PROGRAM INCLUDES THREE GLOBAL STUDIES IN CHILDREN​.  Full Article

DBV Technologies reports at Sept. 30 cash position of 170.5 million euros
Tuesday, 31 Oct 2017 12:58pm EDT 

Oct 31 (Reuters) - DBV TECHNOLOGIES SA ::CASH POSITION AT SEPT. 30, 2017 EUR 170.5 MILLION VERSUS EUR 256.5 MILLION AT DEC. 31, 2016 ‍​.  Full Article

DBV Technologies ‍cash position of 170.5 million euros as of September 30​
Tuesday, 31 Oct 2017 02:44am EDT 

Oct 31 (Reuters) - DBV TECHNOLOGIES SA ::‍CASH AND CASH EQUIVALENTS AS OF SEPTEMBER 30, 2017, WERE EUR 170.5 MILLION, COMPARED TO EUR 256.5 MILLION AS OF DECEMBER 31, 2016.​.  Full Article

DBV Technologies peanut allergy treatment fails to meet main goal in late-stage study
Friday, 20 Oct 2017 05:41pm EDT 

Oct 20 (Reuters) - Dbv Technologies Sa :DBV Technologies announces topline results of phase III clinical trial in peanut-allergic patients four to 11 years of age‍​.DBV Technologies - topline results show statistically significant response with a favorable tolerability profile.DBV Technologies - primary endpoint did not reach 15% lower bound of CI that was proposed in study’s statistical analysis plan‍​.DBV Technologies - DBV will continue ongoing discussions with FDA, and plans to proceed with the BLA preparation process.  Full Article

DBV Technologies initiates phase III study of Viaskin peanut
Wednesday, 2 Aug 2017 01:30am EDT 

Aug 2 (Reuters) - DBV TECHNOLOGIES SA :REG-DBV TECHNOLOGIES INITIATES PHASE III STUDY OF VIASKIN PEANUT IN PEANUT-ALLERGIC PATIENTS ONE TO THREE YEARS OF AGE.  Full Article

DBV Technologies H1 net loss widens to EUR 72.5 million
Friday, 28 Jul 2017 01:30am EDT 

July 28 (Reuters) - DBV TECHNOLOGIES SA ::CASH POSITION: CASH AND CASH EQUIVALENTS AS OF JUNE 30, 2017, WERE €198.7 MILLION‍​.OPERATING INCOME: OPERATING INCOME WAS €7.6 MILLION FOR THE FIRST HALF 2017 COMPARED TO €4.8 MILLION FOR THE PRIOR-YEAR PERIOD.NET LOSS: NET LOSS WAS €72.5 MILLION FOR THE FIRST HALF 2017, COMPARED TO €49.4 MILLION FOR THE FIRST HALF 2016..  Full Article

BRIEF-DBV Technologies Reports Cash position of 234.5 Million Euros at end March

* CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018, WERE EUR 234.5 MILLION Source text for Eikon: Further company coverage: (Gdynia Newsroom)